SARAH LAND: Open Payments
NPI 1700956406 · TULSA, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$112,589 in 335 payments from 16 companies in 2025. Trend: 2023 $49,094 · 2024 $50,175 · 2025 $112,589
Speaker / faculty: $91,225Consulting: $12,250Food & beverage: $5,351Travel & lodging: $3,738Education: $26
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 62 | $41,642 |
| Otsuka America Pharmaceutical, Inc. | 42 | $30,926 |
| E.R. Squibb & Sons, L.L.C. | 38 | $19,282 |
| Alkermes, Inc. | 52 | $18,564 |
| Vanda Pharmaceuticals Inc. | 34 | $430 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 20 | $414 |
| Corium, LLC | 21 | $244 |
| Supernus Pharmaceuticals, Inc. | 15 | $241 |
| Neurocrine BioSciences, Inc. | 17 | $235 |
| Janssen Pharmaceuticals, Inc | 14 | $230 |
Products named: VRAYLAR, REXULTI, LYBALVI, COBENFY, ARISTADA, FANAPT, CAPLYTA, ABILIFY MAINTENA.
Industry payments across OK — which companies pay providers there.
